Home » Stocks » EXAS

Exact Sciences Corporation (EXAS)

Stock Price: $118.19 USD 2.32 (2.00%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $119.44 +1.25 (1.06%) Nov 27, 4:51 PM

Stock Price Chart

Key Info

Market Cap 18.80B
Revenue (ttm) 1.32B
Net Income (ttm) -333.78M
Shares Out 159.03M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $118.19
Previous Close $115.87
Change ($) 2.32
Change (%) 2.00%
Day's Open 117.32
Day's Range 116.00 - 121.06
Day's Volume 1,390,903
52-Week Range 35.25 - 141.90

More Stats

Market Cap 18.80B
Enterprise Value 19.23B
Earnings Date (est) Feb 25, 2021
Ex-Dividend Date n/a
Shares Outstanding 159.03M
Float 157.38M
EPS (basic) -2.13
EPS (diluted) -2.27
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.58M
Short Ratio 5.30
Short % of Float 7.36%
Beta 1.89
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 14.23
PB Ratio 7.46
Revenue 1.32B
Operating Income -448.83M
Net Income -333.78M
Free Cash Flow -91.69M
Net Cash -430.68M
Net Cash / Share -2.71
Gross Margin 49.94%
Operating Margin -33.99%
Profit Margin -25.30%
FCF Margin -6.94%
ROA -4.09%
ROE -21.63%
ROIC -17.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (15)

Buy 12
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$150.43*
(27.28% upside)
Low
140
Current: $118.19
High
161
Target: 150.43
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue87645426699.3839.441.804.144.144.165.34
Revenue Growth92.82%70.86%167.66%151.99%2093.38%-56.61%0%-0.46%-22.1%-
Gross Profit66033818854.1814.94-2.534.144.144.145.32
Operating Income-234-159-118-169-159-101-46.76-52.64-28.82-11.83
Net Income-83.99-175-114-167-158-100-46.51-52.42-28.68-11.56
Shares Outstanding13112211610292.1480.2367.4959.4852.5140.46
Earnings Per Share-0.64-1.43-0.99-1.63-1.71-1.25-0.69-0.88-0.54-0.29
Operating Cash Flow-115-69.33-71.72-130-134-81.46-40.28-44.52-27.46-13.44
Capital Expenditures-172-150-48.48-14.85-21.98-11.99-8.75-0.68-2.12-0.63
Free Cash Flow-287-219-120-145-156-93.45-49.03-45.20-29.58-14.07
Cash & Equivalents3241,12442531130728313310893.3695.42
Total Debt9556894.454.814.961.361.712.041.001.00
Net Cash / Debt-63143542030630228113210692.3694.42
Assets3,5061,52459937736431314711296.9596.52
Liabilities1,21884378.1441.7537.1723.8411.3113.5213.4616.76
Book Value2,28868152033532728913598.6083.5079.75
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Exact Sciences Corporation
Country United States
Employees 4,110
CEO Kevin T. Conroy

Stock Information

Ticker Symbol EXAS
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: EXAS

Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.